Moderna’s combined mRNA vaccine for Covid and flu outperformed existing standalone vaccines in a phase 3 clinical trial, according to results published in the Journal of the American Medical Association. Funded by Moderna, the trial involved over 8,000 adults aged 50 and older. Participants received either the combination vaccine or separate shots for comparison. The trial focused on antibody responses against multiple influenza strains and the XBB.1.5 Covid variant. Results showed higher antibody levels for Covid and most flu strains in those receiving the combo vaccine. Experts noted a 20%-40% increase in antibody levels, suggesting improved protection. Side effects like fever and chills were more common with the new vaccine, attributed to the immune system’s response to both viruses simultaneously. A combination shot could simplify vaccination schedules, especially as both vaccines are typically administered in the fall. Moderna anticipates FDA approval by 2026, pending further efficacy data. The trial’s success highlights mRNA technology’s potential for multi-pathogen vaccines. — new from NBC News
